FLEXIPIL
FLEXIPIL, licence 80036415: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Nutreos BioSciences Inc.
- NPN or DIN-HM
- 80036415
- Status
- Active licence
- Licence date
- 12 October 2012
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Glycyrrhiza uralensis Fisch.: La portion journalière recommandée ne doit pas conduire à une ingestion d'acide glycyrrhizinique supérieure à 100 mg. L'étiquetage doit comporter un avertissement avec la teneur suivante: "Ne pas utiliser pendant plus de 6 semaines sans avis médical." L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les enfants.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Dioscorea villosa L.: Les matières premières végétales doivent avoir subi les étapes traditionnelles d'épluchage, de lavage et de traitement thermique. L'absence d'alcaloïdes et de composés cyanogènes doit être démontrée par des bulletins d'analyse.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Boswellia serrata Source : Gomme (extrait normalisé) Extraction ratio : 5:1 Dry plant equivalent : 112.5 mg Potency : 10.0 % boswellic acid | 22.5 mg | Not calculated |
| Boswellia serrata Source : Résine de gomme Extraction ratio : 5:1 Dry plant equivalent : 112.5 mg Potency : 10.0 % boswellic acid | 22.5 mg | Not calculated |
| Saposhnikovia divaricata Source : Extrait de racine Extraction ratio : 4.334:1 Dry plant equivalent : 65.01 mg | 15.0 mg | Not calculated |
| Glycyrrhiza uralensis Source : Root extract (standardised) Extraction ratio : 5:1 Dry plant equivalent : 37.5 mg Potency : 15.0 % glycyrrhizin | 7.5 mg | Not calculated |
| Dioscorea villosa Source : Root extract (standardised) Extraction ratio : 5:1 Dry plant equivalent : 37.5 mg Potency : 3.0 % diosgenin | 7.5 mg | Not calculated |
| Angelica sinensis Source : Root (standardized extract) Extraction ratio : 4.334:1 Dry plant equivalent : 65.01 mg Potency : 2.0 % ligustilide | 15.0 mg | Not calculated |
| Cinnamomum aromaticum Source : Stem bark extract Extraction ratio : 4.956:1 Dry plant equivalent : 55.755 mg Potency : 5.0 % cinnamaldehyde | 11.25 mg | Not calculated |
| Cinnamomum aromaticum Source : Extrait d'écorce normalisé Extraction ratio : 4.956:1 Dry plant equivalent : 55.755 mg Potency : 5.0 % cinnamaldehyde | 11.25 mg | Not calculated |
| Sulfate de 2-amino-2-désoxy-D-glucose Source : Sulfate de glucosamine chlorure de pottasium provenant d¿exosquelettes de crevettes | 375.0 mg | Not calculated |
| Curcuma longa Source : Rhizome Extract Extraction ratio : 5:1 Dry plant equivalent : 37.5 mg Potency : 8.0 % curcumin | 7.5 mg | Not calculated |
| Harpagophytum procumbens Source : Dried secondary root tuber extract Extraction ratio : 5:1 Dry plant equivalent : 112.5 mg Potency : 5.0 % harpagosides | 22.5 mg | Not calculated |
Non-medicinal ingredients
Gélatine, Maltodextrine, Stéarate de magnésium, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2.0 Capsule | 2.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to relieve joint pain associated with osteoarthritis. Helps to relieve pain associated with osteoarthritis of the knee. Helps to protect against the deterioration of cartilage. A factor in maintaining good cartilage and/or joint health. Provides antioxidants for the maintenance of good health.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80036415
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.